病毒性肝炎、药物或毒素可促使无慢性肝病患者发生急性肝衰。代谢应激反应(例如出血或感染)可加速慢性肝病患者发生亚急性(acute on Chronic)肝衰。人工与生物人工支持系统治疗目的是使肝衰患者过渡至肝移植或自行恢复。肝支持疗法需包...病毒性肝炎、药物或毒素可促使无慢性肝病患者发生急性肝衰。代谢应激反应(例如出血或感染)可加速慢性肝病患者发生亚急性(acute on Chronic)肝衰。人工与生物人工支持系统治疗目的是使肝衰患者过渡至肝移植或自行恢复。肝支持疗法需包括清除毒素产物合成与治疗炎症。最初的人工支持系统是通过血液透析。展开更多
Liver transplantation and blood purification therapy,including plasmapheresis,hemodiafiltration,and bioartificial liver support,are the available treatments for patients with severe hepatic failure.Bioartificial liver...Liver transplantation and blood purification therapy,including plasmapheresis,hemodiafiltration,and bioartificial liver support,are the available treatments for patients with severe hepatic failure.Bioartificial liver support,in which living liver tissue is used to support hepatic function,has been anticipated as an effective treatment for hepatic failure.The two mainstream systems developed for bioartificial liver support are extracorporeal whole liver perfusion(ECLP)and bioreactor systems.Comparing various types of bioartificial liver in view of function,safety,and operability,we concluded that the best efficacy can be provided by the ECLP system.Moreover,in our subsequent experiments comparing ECLP and apheresis therapy,ECLP offers more ammonia metabolism than HD and HF.In addition,ECLP can compensate amino acid imbalance and can secret bile.A controversial point with ECLP is the procedure is labor intensive,resulting in high costs.However,ECLP has the potential to reduce elevated serum ammonia levels of hepatic coma patients in a short duration.When these problems are solved,bioartificial liver support,especially ECLP,can be adopted as an option in ordinary clinical therapy to treat patients with hepatic failure.展开更多
文摘病毒性肝炎、药物或毒素可促使无慢性肝病患者发生急性肝衰。代谢应激反应(例如出血或感染)可加速慢性肝病患者发生亚急性(acute on Chronic)肝衰。人工与生物人工支持系统治疗目的是使肝衰患者过渡至肝移植或自行恢复。肝支持疗法需包括清除毒素产物合成与治疗炎症。最初的人工支持系统是通过血液透析。
文摘Liver transplantation and blood purification therapy,including plasmapheresis,hemodiafiltration,and bioartificial liver support,are the available treatments for patients with severe hepatic failure.Bioartificial liver support,in which living liver tissue is used to support hepatic function,has been anticipated as an effective treatment for hepatic failure.The two mainstream systems developed for bioartificial liver support are extracorporeal whole liver perfusion(ECLP)and bioreactor systems.Comparing various types of bioartificial liver in view of function,safety,and operability,we concluded that the best efficacy can be provided by the ECLP system.Moreover,in our subsequent experiments comparing ECLP and apheresis therapy,ECLP offers more ammonia metabolism than HD and HF.In addition,ECLP can compensate amino acid imbalance and can secret bile.A controversial point with ECLP is the procedure is labor intensive,resulting in high costs.However,ECLP has the potential to reduce elevated serum ammonia levels of hepatic coma patients in a short duration.When these problems are solved,bioartificial liver support,especially ECLP,can be adopted as an option in ordinary clinical therapy to treat patients with hepatic failure.
